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ABSTRACT
Objective: We provide a nationwide population study of patients with congenital muscular
dystrophy in Italy.
Methods: Cases were ascertained from the databases in all the tertiary referral centers for pedi-
atric neuromuscular disorders and from all the genetic diagnostic centers in which diagnostic
tests for these forms are performed.
Results: The study includes 336 patients with a point prevalence of 0.563 per 100,000. Muta-
tions were identified in 220 of the 336 (65.5%). The cohort was subdivided into diagnostic
categories based on the most recent classifications on congenital muscular dystrophies. The
most common forms were those with a-dystroglycan glycosylation deficiency (40.18%) followed
by those with laminin a2 deficiency (24.11%) and collagen VI deficiency (20.24%). The forms of
congenital muscular dystrophy related to mutations in SEPN1 and LMNA were less frequent
(6.25% and 5.95%, respectively).
Conclusions: Our study provides for the first time comprehensive epidemiologic information and
point prevalence figures for each of the major diagnostic categories on a large cohort of congen-
ital muscular dystrophies. The study also reflects the diagnostic progress in this field with an
accurate classification of the cases according to the most recent gene discoveries. Neurology®
2015;84:904–911
GLOSSARY
aDG 5 a-dystroglycan; CK 5 creatine kinase; CMD 5 congenital muscular dystrophy; MEB 5 muscle-eye-brain disease;
RSMD1 5 rigid spine muscular dystrophy type 1.
The term congenital muscular dystrophy (CMD) classically includes a group of genetically, clin-
ically, and biochemically distinct entities sharing clinical and pathologic features such as early
presentation of weakness and hypotonia and dystrophic features on muscle biopsy.1
The rapidly increasing identification of several genes responsible for different forms of CMD
has dramatically expanded the spectrum of the known forms, allowing a better understanding of
the individual forms and different underlying pathomechanisms.2
The incidence and prevalence of CMD in populations is not sufficiently known with only a
few studies reporting incidence or point prevalence in relatively small regions.3–5 Furthermore,
several new genes have only been described in the last few years and the subtyping and classi-
fication in those reports is therefore not updated.
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In this study, we report the results of a
detailed population study and the frequency
of the various forms of CMD in all the patients
with CMD referred to all the tertiary care cen-
ters for pediatric neuromuscular disorders in
Italy.
METHODS Our inclusion criteria were all patients with a diag-
nosis of CMD currently seen in the participating centers. The
diagnosis of CMD was based on a combination of clinical and
biopsy findings according to the recently proposed diagnostic cri-
teria for CMD.6 This included clinical signs suggestive of CMD
and/or dystrophic or myopathic features on muscle biopsy, with
exclusion of other identifiable neuromuscular disorders. Clinical
signs included weakness and hypotonia or contractures at birth or
in the first months, but as in some CMD variants (e.g., Ullrich
CMD), the onset can be delayed.6–8
All patients with a potential neuromuscular disorder, with
weakness and/or increased creatine kinase (CK) serum levels, are
referred to a tertiary care center for further testing. Because all
the Italian tertiary care centers for pediatric and adult neuromuscu-
lar disorders participated in this study, we are therefore likely to
have included all the patients who have undergone a diagnostic pro-
cess for CMD. Cases were ascertained from the databases in each
center, only including patients who were under current follow-
up. To exclude that patients may have been referred by other physi-
cians, we also checked all the molecular genetic centers performing
analysis of the CMD genes. Other sources available for this study
included the Collagen VI Database held at the University of Ferrara
and the CMD Dystroglycan Database, a nationwide database used
for our previous study9,10 and that is constantly updated.
Disease groups were established using the most recent CMD
classifications2 (table 1):
1. Forms of CMD due to mutations in genes encoding for struc-
tural proteins of the basal lamina or extracellular matrix or
receptors for extracellular matrix proteins. This category in-
cludes mutations in the collagen 6 genes, laminin a2 (merosin),
and integrin a7 and a9.
2. Forms secondary to genes encoding for putative or demon-
strated glycosyltransferases, which affect the glycosylation of
a-dystroglycan (aDG). This includes Fukuyama CMD,
muscle-eye-brain disease (MEB), and Walker-Warburg syn-
drome, and other phenotypes.
3. Forms due to mutations in genes encoding for nuclear enve-
lope proteins (LMNA and nesprin).
4. Forms due to abnormalities of proteins with, so far, unknown
function localized in the endoplasmic reticulum, which
include the form of CMD with rigid spine syndrome second-
ary to mutations in SEPN1.
For each group, and for the whole cohort, point prevalence
was established. The prevalence day was January 31, 2013. The
95% confidence interval was measured using the Wilson score
interval with continuity correction.
Standard protocol approvals, registrations, and patient
consents. The ethical committees of the participating centers
approved the study.
RESULTS Three hundred thirty-six subjects fulfilled
the inclusion criteria (191 male, 145 female). All were
followed by one of the participating clinical centers
who were also responsible for referring them for the
genetic diagnosis with the exception of 2 boys with
Ullrich CMD referred to the genetic labs by a
specialist in connective tissue disorders. After diagnosis,
both patients were referred and followed by one of the
clinical participating centers.
The combined prevalence was 0.563 per 100,000
total population. More than 90% could be classified
in one of the major diagnostic groups. Mutations
were identified in 220 of the 336. Table 2 shows
details for each subgroup.
Major diagnostic categories. Dystroglycanopathies. This
group comprised 135 patients, 40.18% of the
CMD population, with a prevalence of 0.226 per
100,000. In these patients, the diagnosis of dystrogly-
canopathy followed the evidence of predominant
weakness and wasting of the upper compared with
the lower limbs, and markedly elevated serum CK
levels. In a minority of cases, the diagnosis followed
clinical and radiologic evidence of CNS involvement
in the first months of life, associated with highly
increased values of CK serum levels (more than 5-
fold the normal values). In all, muscle biopsy showed
absent or reduced aDG.
The form with mental retardation and microceph-
aly with or without cerebellar involvement and MEB
were the most frequent phenotypes.
Mutations were identified in 75 of the 135 patients
with aDG reduction included in the present study. All
135 were screened for the 6 genes identified before
2012 (namely, FKRP, POMT1, POMT2, POMGnT1,
Fukutin, LARGE). Sixty-seven patients (49.62%) had
2 allelic mutations identified in one of these 6 genes.
By subtype of mutations, POMT1 was the most com-
mon, representing 15.5% of the total dystroglycano-
pathies, followed by FKRP, POMGnT1, and POMT2
(12.59%, 10.37%, and 9.62%, respectively). Details
of the occurrence of each form are shown in table 2.
The other categories were individually much smaller
with only isolated cases with mutations in LARGE or
Fukutin.
Of the 68 subjects who did not have mutations in
the first 6 genes identified, only a subset of 18 was
screened for the more recently discovered genes. Muta-
tions were found in 8 of these 18, raising the number
of patients with identified mutation from 67 to 75 of
135. Three subjects had mutations in ISPD, 2 in
DPM2, 2 inGSPPMD, and 1 in B3GALNT2. Because
genetic analysis for the remaining 50 is in progress, we
cannot therefore yet fully establish the prevalence of
mutations in the new genes.
Nine of the 135 patients were familial cases (5 sets
of siblings; one of them had a sibling not included in
the present study). All the patients in this group were
of Italian origin with the exception of 16 who were
resident in Italy but with parents originally from
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other countries (8 from Northern Africa, 4 from East-
ern Europe, and 4 from Asia).
Merosin-deficient CMD. Eighty-one patients were
classified as laminin a2 (merosin)-deficient CMD
(24.11% of the whole CMD cohort) with a preva-
lence of 0.136 per 100,000 for Italy.
All had a phenotype consistent with the classic
course of typical phenotype reported for merosin-
deficient CMD including the involvement of the
white matter on brain MRI,8,11 and increased CK
(more than 5-fold the normal values).
LAMA2 chain gene mutations were found in 51 of
81. In 7 patients, genetic analysis for LAMA2 is in
progress or consent was not obtained by the parents.
In the remaining 23 patients, mutations were not
found; of these, 21 patients had absent or markedly
reduced laminin a2 and 2 partial deficiency on mus-
cle biopsy. In the 2 cases with partial deficiency, the
reduction in laminin a2 expression was greater than
the reduction observed in aDG protein expression.
Both were also screened for the first 6 genes identified
for dystroglycanopathies and no mutation was found.
Table 1 Classification of CMD
Locus Gene Disease phenotype
Extracellular matrix proteins
6q22-23 LAMA2 Primary merosin deficiency
21q22.3 COL6A1/COL6A2 Ullrich CMD
2q37 COL6A3
External sarcolemmal proteins
12q13 ITGA7 Integrin a7–related CMD
3p23-21 ITGA9 Integrin a9–related CMD
Dystroglycan and glycosyltransferase
enzymes
9q34.1 POMT1 WWS, MEB, CMD with cerebellar involvement, CMD with
mental retardation and microcephaly
1q32-34 POMGnT1 WWS, MEB, CMD with cerebellar involvement
14q24.3 POMT2 WWS, MEB, CMD with cerebellar involvement, CMD with
mental retardation and microcephaly
19q13.3 FKRP WWS, MEB, CMD with cerebellar involvement, CMD with
mental retardation and microcephaly, CMD with no mental
retardation
9q31 FCMD Fukuyama CMD
22q12.3-13.1 LARGE WWS, MEB, white matter changes
1q12-q21 DPM2/DPM3 CMD with mental retardation and severe epilepsy
7p21.2 ISPD WWS, LGMD
3p22.1 GTDC2 WWS
11q13.2 B3GALNT2 WWS, MEB
3p21.23 GMPPB CMD with mental retardation and severe epilepsy, LGMD
3p21 DAG1 Primary dystroglycanopathy, LGMD with early onset and
mental retardation, normal brain MRI
8p11.21 SGK196 MEB
1q42 — MDC1B
Endoplasmic reticulum protein
1p35-36 SEPN1 CMD with spinal rigidity (RSMD1)
Nuclear envelope proteins
6q25 SYNE1 (nesprin 1) CMD with adducted thumbs
1q21.2 LMNA Congenital laminopathy
Sarcolemmal and mitochondrial
membrane protein
22q13 CHKB Mitochondrial CMD (CMDmt)
Abbreviations: CMD 5 congenital muscular dystrophy; CMDmt 5 CMD with mitochondrial structural abnormalities; LGMD 5
limb-girdle muscular dystrophy; MDC1B 5 muscular dystrophy, congenital, 1B; MEB 5 muscle-eye-brain disease; RSMD1 5
rigid spine muscular dystrophy type 1; WWS 5 Walker-Warburg syndrome.
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Sixteen cases were familial (6 sets of siblings and 2
couples of first cousins). Sixty patients in this group
were of Italian origin while the other 21 were resident
in Italy but had parents originally from other coun-
tries (14 from Northern Africa, 3 from Eastern
Europe, 3 from Asia, and 1 from South America).
Ullrich CMD. Sixty-eight patients (20.24%) had a
phenotype compatible with Ullrich CMD and
reduced collagen on skin and or muscle biopsy. CK
levels were normal or only mildly elevated. Muscle
MRI was available in 32 of the 64 and showed the
typical pattern previously reported in association with
Ullrich CMD.12 The point prevalence was 0.114 per
100,000.
Mutations were found in 55 of the 68. Regarding
the phenotypes, 11 cases were familial (5 sets of sib-
lings) and none had other familial cases not included
in the present study. All the patients in this group
were of Italian origin with the exception of 9 who
were resident in Italy but with parents originally from
other countries (2 from South America, 2 from
Northern Africa, 2 from Eastern Europe, 1 from Asia,
and 2 from Turkey).
Fifty-five cases with COL6 mutations in whom
ambulation was achieved by 24 months and the onset
of weakness or contractures occurred after that, were
not classified as CMD and therefore not included in
the present study.
Rigid spine muscular dystrophy type 1. Twenty-one pa-
tients (6.25%) had delayed ambulation, developed rigid
spine and early respiratory impairment, with a clinical
and MRI phenotype compatible with rigid spine mus-
cular dystrophy type 1 (RSMD1). Serum CK levels
were normal or only mildly elevated. Muscle MRI
Table 2 Analysis of cases by disease group
Disease group
No. of cases based
on clinical diagnosis
Proportion (%) of clinic
population affected (95% CI)
Estimated point prevalence
per 100,000 (95% CI)
Dystroglycanopathies 135 40.18 (34.93–45.65) 0.226 (0.19–0.268)
Mutation found 75 22.32 (18.06–27.23) 0.126 (0.1–0.159)
FKRP 17 5.06 (3.07–8.13) 0.028 (0.017–0.045)
POMT1 21 6.25 (4–9.54) 0.035 (0.022–0.055)
POMT2 13 3.87 (2.17–6.69) 0.022 (0.012–0.039)
POMGnT1 14 4.17 (2.39–7.06) 0.023 (0.013–0.04)
LARGE 1 0.29 (0.05–1.64) 0.002 (0–0.011)
FUKUTIN 1 0.29 (0.05–1.64) 0.002 (0–0.011)
DPM2 2 0.6 (0.1–2.38) 0.003 (0–0.013)
ISPD 3 0.89 (0.23–2.8) 0.005 (0.001–0.016)
GSPPMD 2 0.6 (0.1–2.38) 0.003 (0–0.013)
B3GALNT2 1 0.29 (0.05–1.64) 0.002 (0–0.011)
In progress 11 3.27 (1.73–5.95) 0.018 (0.009–0.033)
No mutation found (6 aDG) 49 14.58 (11.08–18.92) 0.082 (0.061–0.109)
Laminin a2–deficient CMD 81 24.11 (19.71–29.12) 0.136 (0.109–0.17)
Mutation found 51 15.18 (11.61–19.57) 0.085 (0.064–0.113)
In progress 7 2.08 (0.09–4.43) 0.012 (0.005–0.026)
No mutation found 23 68.5 (4.61–10.24) 0.039 (0.025–0.059)
Ullrich CMD 68 20.24 (16.16–25.02) 0.114 (0.089–0.014)
Mutation found 55 16.37 (12.67–20.86) 0.092 (0.07–0.121)
In progress 13 3.87 (2.17–6.69) 0.022 (0.012–0.039)
Rigid spine muscular dystrophy 21 6.25 (4–9.54) 0.035 (0.022–0.055)
Mutation found 19 5.65 (3.53–8.83) 0.032 (0.02–0.051)
No mutation found 2 0.6 (0.1–2.38) 0.003 (0–0.013)
LMNA 20
Mutation found 20 5.95 (3.77–9.19) 0.034 (0.021–0.053)
Others
No mutation found 11 3.27 (1.73–5.95) 0.18 (0.009–0.037)
Abbreviations: aDG 5 a-dystroglycan; CI5 confidence interval; CMD5 congenital muscular dystrophy; LMNA 5 lamin A/C.
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was available in 18 and showed the typical pattern pre-
viously reported in association with SEPN1 muta-
tions.12 Mutations in SEPN1 were found in 19 of the
21. The point prevalence was 0.035 per 100,000.
They were all sporadic cases, with the exception of
2 siblings. All the patients in this group were of Italian
origin with the exception of 2 whose parents were
originally from South Asia.
Laminopathies. Twenty patients (5.95%) had con-
genital presentation with dropped head or other clini-
cal signs suggestive of the form of CMD associated
with laminopathy. All but 4 achieved independent
ambulation. Mutations in LAMA A/C were found in
all 20. The point prevalence was 0.034 per 100,000.
They were all sporadic cases with the exception of
a girl whose father was also affected and had died of
cardiac arrhythmia. All were of Italian origin with
the exception of one child whose parents were origi-
nally from South Asia.
Other cases. Eleven cases fulfilled the inclusion crite-
ria for CMD but did not fit into any of the previous
major categories. All had increased CK, ranging from
2- to 8-fold the normal values. Three had signs of
CNS involvement but normal laminin a2 and aDG
on muscle biopsy.
DISCUSSION The population prevalence figure for
CMD in our study was 0.563 per 100,000. Because
all the Italian tertiary care centers for neuromuscular
disorders participated in this study, this figure is likely
to include all cases with a clinical presentation evoca-
tive of a CMD phenotype or at least all those for
whom a possible diagnosis of CMD was considered.
We cannot exclude that in some cases with milder
phenotypes or later onset, the diagnosis of CMD
may not have been considered and these patients
may have never been referred to a tertiary care center
or had any diagnostic test for CMD performed.
In this study, we subdivided our cohort according
to the most recent classification for CMD. Because of
this, the results are not easily comparable with previ-
ous population studies as most of them only included
small cohorts and/or were performed before the iden-
tification of new genes.
In 1996, the incidence of CMD was estimated at
between 4.7 3 105 live births in the north of Italy,5
but only 20 patients with CMD were included.
Another study reports a point prevalence of 6.3 3
105 in 20 patients identified in Western Sweden as
part of a larger epidemiologic study in neuromuscular
disorders in childhood.3 In all these cases, no subtyp-
ing of the different forms of CMD was available. A
more recent study4 exploring the prevalence of all the
genetic muscle disease in Northern England reports a
prevalence of CMD of 0.76 3 105 with 26 CMD
cases subdivided into 4 major subtypes.
Other recent studies have investigated larger co-
horts of CMDs reporting the relative frequencies of
CMD subtypes,13,14 but these mainly reflected the
activity of diagnostic centers and were not population
studies.
More than 85% of our patients are of Italian ori-
gin, and when we analyzed their postcodes, we were
unable to identify any obvious correlation between
individual forms and local regional areas.
Dystroglycanopathies were the most common
group of CMD in our database (40.18%), followed
by merosin-deficient CMD (24.11%) and Ullrich
CMD (20.24%). No data on the prevalence of the
individual forms are available for comparison in the
population studies3,5 published before the last decade.
Our data appear to be different from the large diag-
nostic UK study reporting that dystroglycanopathies
were present in 12% of the whole CMD cohort,
although that study only considered patients in whom
a final genetic diagnosis was reached between 2001
and 2008.14 It is possible that regional differences
may also have a role in the variability observed in
different countries.
Among our cohort of dystroglycanopathies, the
most frequent phenotypes observed were microceph-
aly and mental retardation, with or without cerebellar
abnormalities, previously labeled as Italian MEB, and
the typical MEB phenotype.15 These phenotypes
were also found to be among the most frequent in
the large UK study.16–18
All the cases identified as dystroglycanopathies
were further subdivided according to the gene muta-
tions. POMT1 mutations were the most frequent,
followed by FKRP, POMGnT1, and POMT2. In
14.58%, a mutation could not be identified, but most
of them have not yet been systematically screened for
all the recently discovered genes. The detection rate of
mutations in the subset of cases that had already been
screened for all genes suggests that the full screening is
likely to markedly reduce the number of cases in
whom mutations cannot be identified.
The next major group was laminin a2–deficient
CMD (24.11% of the whole CMD cohort) with an
estimated point prevalence of 0.136 per 100,000. This
form has often been reported to be the most frequent
form of CMD, with values up to 40% of the CMD
cases.11,19 More recent studies13,14,20 report values sim-
ilar to those found in our cohort.
Twenty-three of the 81 cases in our cohort (28%)
had a typical clinical phenotype consistent with
merosin-deficient CMD, associated with absent or
marked reduction of laminin a2 on muscle biopsy
and classic white matter changes on brain MRI, but
no mutation could be identified. With the exception
of 7 previous cases in whom DHPLC (denaturing
high-performance liquid chromatography) was used,
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Sanger sequencing of the entire coding region was
performed in all. It is possible that these patients have
deep intronic variants, which affected splicing or exon
deletions or duplications, not easily detectable by the
standard mutation detection methods used.
Forms with congenital presentation and collagen
VI involvement were found in 20.24% of our cohort
with similar values to that observed in the large UK
series14 (21%). Mutations were found in all but one
of those in whom the analysis has been completed.
The high rate of detection may be explained by the
fact that all these cases had the typical phenotype
characterized by distal laxity, skin changes, rigid
spine, and early respiratory impairment. The combi-
nation of these clinical findings with reduction of
collagen 6 on skin cultures and muscle biopsy and,
when performed, of the typical muscle MRI changes,
appear to increase the possibility of finding mutations
in the COL6 genes. Because of our strict inclusion
criteria, we may have missed some of the milder
Ullrich CMD or of the recently described intermediate
phenotype21 that had normal early milestones, includ-
ing age of ambulation and onset of clinical signs after
the age of 2 years. All the patients with Bethlemmyop-
athy had onset of clinical signs after ambulation was
achieved and were therefore not included.
Mutations in SEPN1 were found in 19 of the 21
patients in whom the clinical phenotype was consis-
tent with that reported in RSMD22,23 even though it
was not always easy to establish retrospectively
whether these should be classified as minicore myo-
pathies or RSMD1 because of the marked clinical and
pathologic overlap between these forms.24
Because of its retrospective nature, our study has
some limitations as the patients included had biopsies
performed in different laboratories and from the re-
ports it was not always easy to compare the severity
of changes on muscle biopsies. Similarly, data on the
antibodies used for assessing laminin a2 were not
always consistent because the samples were processed
at different times. This should be systematically reas-
sessed, revaluating the biopsies using similar classifica-
tion criteria.
Mutations were identified in 220 of the 336
(65%), but in a proportion of cases, analysis of newly
identified genes is still in progress. It is of interest that,
even though genetic confirmation was not achieved in
all, approximately 90% of our cases could be ascribed
to one of the major clinical categories. This is proba-
bly related to the fact that the diagnosis was based on
an integrated approach including clinical, pathologic,
genetic, and often MRI features rather than on the
analysis of samples sent by other centers with reported
information. This approach has also allowed identifi-
cation of a number of patients, formerly labeled as
CMD in the past, with mutations in other genes
responsible for other disorders such as congenital
myopathies or congenital myasthenia, that have a
clinical and pathologic overlapping with CMD.
Another strength is that the genetic testing for the
major categories such as dystroglycanopathies or colla-
genopathies is centralized and this guarantees that all
the cases in whom the diagnosis of these categories
was suspected have been included. Work is in progress
to improve the detection rate of merosin-deficient
CMD, using RNA studies or other genomic techni-
ques such as MLPA (multiplex ligation-dependent
probe amplification) or DNA arrays. Should this more
comprehensive approach not detect any mutation,
these patients would allow exploring possible genetic
heterogeneity in this subgroup.
Further work has also been planned to perform
further sequencing including next-generation
sequencing to detect the more rare forms of CMD
such as nesprin that have not been systematically
investigated in our unresolved cases.
Our results clearly show how the detection rate of
mutations has increased following the increased num-
ber of new genes identified. We foresee that even
screening for all the known genes, a proportion will still
remain without a diagnosis and that further CMD sub-
types and genes are yet to be discovered.
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